AKT1 and neoplasm: As preclinical and clinical tumor therapies targeting Akt-related pathways spring out robustly in the past decade, we envision that the future CDKL3-specific inhibitors may join the rank either individually or combinatorically (Fruman & Rommel, 2014; Zhang et al, 2015; Mundi et al, 2016).